ALTEOGEN Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2008-05-13
- Employees
- 131
- Market Cap
- $12.6B
- Website
- http://www.alteogen.com
Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Alteogen, Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT05232175
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Alteogen, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04058535
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Alteogen, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03281824
- Locations
- 🇰🇷
Alteogen, Daejeon, Korea, Republic of
A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Alteogen, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03242239
© Copyright 2024. All Rights Reserved by MedPath